menu
    • menu
    [{"orgOrder":0,"company":"Societal CDMO","sponsor":"Xequel Bio","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Agreement","leadProduct":"iNexin","moa":"CX43","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Societal CDMO","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Societal CDMO \/ Societal CDMO","highestDevelopmentStatusID":"6","companyTruncated":"Societal CDMO \/ Societal CDMO"},{"orgOrder":0,"company":"Societal CDMO","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Funding","leadProduct":"Enkephalin","moa":"Delta-opioid receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"Societal CDMO","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Societal CDMO \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Societal CDMO \/ National Institutes of Health"},{"orgOrder":0,"company":"Societal CDMO","sponsor":"Astex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2021","type":"Partnership","leadProduct":"Decitabine","moa":"||DNA (cytosine-5)-methyltransferase 1 | DNA | DNA (cytosine-5)-methyltransferase 3A","graph1":"Oncology","graph2":"Phase III","graph3":"Societal CDMO","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Societal CDMO \/ Astex Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Societal CDMO \/ Astex Pharmaceuticals"},{"orgOrder":0,"company":"Societal CDMO","sponsor":"InfectoPharm Drugs and Consilium","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Miscellaneous","year":"2022","type":"Agreement","leadProduct":"Methylphenidate Hydrochloride","moa":"Dopamine transporter | Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Societal CDMO","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Societal CDMO \/ Societal CDMO","highestDevelopmentStatusID":"15","companyTruncated":"Societal CDMO \/ Societal CDMO"},{"orgOrder":0,"company":"Societal CDMO","sponsor":"InfectoPharm Drugs and Consilium","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Agreement","leadProduct":"Methylphenidate Hydrochloride","moa":"Dopamine transporter | Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Societal CDMO","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Societal CDMO \/ InfectoPharm Drugs and Consilium","highestDevelopmentStatusID":"15","companyTruncated":"Societal CDMO \/ InfectoPharm Drugs and Consilium"},{"orgOrder":0,"company":"Societal CDMO","sponsor":"Atossa Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Agreement","leadProduct":"Endoxifen","moa":"Estrogen receptor (ESR)","graph1":"Oncology","graph2":"Phase II","graph3":"Societal CDMO","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Societal CDMO \/ Atossa Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Societal CDMO \/ Atossa Therapeutics"},{"orgOrder":0,"company":"Societal CDMO","sponsor":"AmyriAD","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Raloxifene Hydrochloride","moa":"Estrogen receptor beta","graph1":"Neurology","graph2":"Phase II","graph3":"Societal CDMO","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Societal CDMO \/ Societal CDMO","highestDevelopmentStatusID":"8","companyTruncated":"Societal CDMO \/ Societal CDMO"},{"orgOrder":0,"company":"Societal CDMO","sponsor":"AmyriAD","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Agreement","leadProduct":"Raloxifene Hydrochloride","moa":"Estrogen receptor beta","graph1":"Neurology","graph2":"Phase II","graph3":"Societal CDMO","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Societal CDMO \/ AmyriAD","highestDevelopmentStatusID":"8","companyTruncated":"Societal CDMO \/ AmyriAD"},{"orgOrder":0,"company":"Societal CDMO","sponsor":"Longboard Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Agreement","leadProduct":"Bexicaserin","moa":"HTR2C","graph1":"Neurology","graph2":"Phase II","graph3":"Societal CDMO","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Societal CDMO \/ Longboard Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Societal CDMO \/ Longboard Pharmaceuticals"},{"orgOrder":0,"company":"Societal CDMO","sponsor":"Cingulate Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Agreement","leadProduct":"Dexmethylphenidate","moa":"Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Societal CDMO","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Societal CDMO \/ Cingulate Therapeutics, LLC","highestDevelopmentStatusID":"10","companyTruncated":"Societal CDMO \/ Cingulate Therapeutics, LLC"},{"orgOrder":0,"company":"Societal CDMO","sponsor":"BioCorRx","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Naltrexone","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Societal CDMO","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Implant","sponsorNew":"Societal CDMO \/ BioCorRx","highestDevelopmentStatusID":"6","companyTruncated":"Societal CDMO \/ BioCorRx"},{"orgOrder":0,"company":"Societal CDMO","sponsor":"Lannett Company, Inc.","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Licensing Agreement","leadProduct":"Verapamil Hydrochloride","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Societal CDMO","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Societal CDMO \/ Lannett Company, Inc.","highestDevelopmentStatusID":"15","companyTruncated":"Societal CDMO \/ Lannett Company, Inc."},{"orgOrder":0,"company":"Societal CDMO","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Societal CDMO","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Societal CDMO \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Societal CDMO \/ Undisclosed"},{"orgOrder":0,"company":"Societal CDMO","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Societal CDMO","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Societal CDMO \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Societal CDMO \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Societal CDMO

    Menu

    Societal CDMO

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    SERVICES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Societal CDMO

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Societal CDMO

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Endoxifen

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Atossa Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Societal CDMO Enters Agreement With Atossa Therapeutics to Provide Clinical Trial Services (CTS) for Innovativ...

                            Details : Under the agreement, Societal CDMO will provide a range of its Clinical Trial Services offerings focused on Atossa’s proprietary Selective Estrogen Receptor Modulator (SERM), (Z)-endoxifen, the most active metabolite of the FDA approved SERM, tamoxifen...

                            Product Name : (Z)-Endoxifen

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            May 23, 2023

                            Lead Product(s) : Endoxifen

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Atossa Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Societal CDMO

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Societal CDMO

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : iNexin

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase I

                            Recipient : Xequel Bio

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Societal CDMO Selected by Xequel Bio to Provide CDMO Services to Support Ongoing Clinical Development of iNexi...

                            Details : Under the agreement, Societal CDMO will provide to support the ongoing clinical development of iNexin™, a patented new chemical entity based on company's aCT1 (alpha-Connexin carboxyl-Terminal 1 peptide) platform.

                            Product Name : iNexin

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Undisclosed

                            May 08, 2023

                            Lead Product(s) : iNexin

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase I

                            Recipient : Xequel Bio

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Societal CDMO

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Societal CDMO

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bexicaserin

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Longboard Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Societal CDMO Selected by Longboard Pharmaceuticals to Provide CDMO Services to Support Clinical Development o...

                            Details : The agreement spans a range of Societal CDMO’s offerings including technology transfer and analytical method validation activities to support Longboard’s Oral, Centrally Acting 5-HT2C Receptor Superagonist, LP352, being developed for treatment of ref...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            April 05, 2023

                            Lead Product(s) : Bexicaserin

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Longboard Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Societal CDMO

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Societal CDMO

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dexmethylphenidate

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase III

                            Sponsor : Cingulate Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Cingulate Announces Agreement with Societal CDMO and Provides Clinical Update

                            Details : Under the agreement, Societal CDMO will manufacture all clinical, registration, and commercial batches of Cingulate’s lead candidate CTx-1301 (dexmethylphenidate), an investigational medication for the treatment of Attention Deficit / Hyperactivity Dis...

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Undisclosed

                            October 24, 2022

                            Lead Product(s) : Dexmethylphenidate

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase III

                            Sponsor : Cingulate Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Societal CDMO

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Societal CDMO

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Societal CDMO Announces Signing of Multiple Agreements With New and Existing Customers

                            Details : The new contracts are focused on a range of analytic method, tech transfer, formulation, manufacturing and packaging services designed to support ongoing clinical development programs, as well as planned commercial activities.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            September 29, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Societal CDMO

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Societal CDMO

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Societal CDMO Adds Three New Customers, Signing Agreements to Provide CDMO Services Supporting Clinical Develo...

                            Details : Under terms of the first new contract, Societal will execute a range of clinical trial services to support the initiation of a U.S.-based Phase 2 clinical study of a novel melatonergic antidepressant already approved for use in Europe and Australia.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            August 04, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Societal CDMO

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Societal CDMO

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Verapamil Hydrochloride

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved FDF

                            Sponsor : Lannett Company, Inc.

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Societal CDMO Announces Signing of Amendment to License and Supply Agreement With Lannett for Marketing of Ver...

                            Details : Under terms of the amendment, Societal will now receive improved overall economics, including a 10% increase in the profit share component of revenue from Verapamil PM product sales, as well as immediate and scheduled increases in manufacturing prices.

                            Product Name : Verelan PM

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            July 12, 2022

                            Lead Product(s) : Verapamil Hydrochloride

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : Lannett Company, Inc.

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Societal CDMO

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Societal CDMO

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Raloxifene Hydrochloride

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Recipient : AmyriAD

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Societal CDMO Selected By AmyriAD Pharma to Provide Clinical Trials Services to Support Pivotal Phase 3 Progra...

                            Details : AD101 (Raloxifene), a 100 Series lead compound and a novel T-type calcium channel modulator demonstrated statistically significant improvement in both core symptoms of AD in Concept Trials.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 01, 2022

                            Lead Product(s) : Raloxifene Hydrochloride

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Recipient : AmyriAD

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Societal CDMO

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Societal CDMO

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Raloxifene Hydrochloride

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : AmyriAD

                            Deal Size : $1.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Societal CDMO Selected By AmyriAD Pharma to Provide Clinical Trials Services to Support Pivotal Phase 3 Progra...

                            Details : Under terms of the new contract, Societal will execute a range of clinical trial services to support the initiation of Phase 3 and Phase 4 clinical studies of AD101 (raloxifene).

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            June 01, 2022

                            Lead Product(s) : Raloxifene Hydrochloride

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : AmyriAD

                            Deal Size : $1.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Societal CDMO

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Societal CDMO

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Methylphenidate Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Approved FDF

                            Recipient : InfectoPharm Drugs and Consilium

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Societal CDMO Signs Three-Year Manufacturing and Supply Agreement With InfectoPharm for Ritalin LA in Europe

                            Details : Ritalin LA is indicated for the treatment of attention deficit hyperactivity disorder. The product is an extended-release formulation of methylphenidate hydrochloride with a bi-modal release profile using the SODAS (Spheroidal Oral Drug Absorption System...

                            Product Name : Ritalin LA

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            May 05, 2022

                            Lead Product(s) : Methylphenidate Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Approved FDF

                            Recipient : InfectoPharm Drugs and Consilium

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth